You Have Rights Blog
FDA Posts List of Potentially Dangerous Prescription Drugs
Monday, September 08, 2008
The U.S. Food and Drug Administration has for the first time posted on its website a list of potentially unsafe prescription drugs – a move officials said is designed to help consumers and physicians better keep track of drugs currently being reviewed for complications. Each of the 20 drugs now on the list is being further evaluated by the FDA for a variety of potentially life-threatening safety problems, side effects, and complications. The list, released as part of the agency’s Adverse Event Reporting System (AERS), will be updated four times each year, officials said. The list of potentially dangerous prescription…
Tysabri Patients Diagnosed With Severe Liver Damage or Melanoma
Tuesday, March 25, 2008
Mark & Associates, P.C. & MacDonald Rothweiler Eisenberg L.L.P. announced that they are evaluating claims of patients treated with the drug Tysabri(r) who have been diagnosed with severe liver damage or melanoma. The announcement comes shortly after the manufacturers of Tysabri, Biogen Idec Inc. (Nasdaq:BIIB) and Elan Corp. plc (NYSE:ELN), warned about reports of liver toxicity in patients treated with the drug following its approval by the Food and Drug Administration, and a letter in the New England Journal of Medicine cautioned doctors about two aggressive cases of malignant melanoma that occurred shortly after the drug was administered. Tysabri(r) patients…
Now Evaluating Claims Involving Tysabri Patients Diagnosed With Severe Liver Damage or Melanoma
Monday, March 03, 2008
Mark & Associates, P.C. & MacDonald Rothweiler Eisenberg L.L.P. announced that they are evaluating claims of patients treated with the drug Tysabri(r) who have been diagnosed with severe liver damage or melanoma. The announcement comes shortly after the manufacturers of Tysabri, Biogen Idec Inc. (Nasdaq:BIIB) and Elan Corp. plc (NYSE:ELN), warned about reports of liver toxicity in patients treated with the drug following its approval by the Food and Drug Administration, and a letter in the New England Journal of Medicine cautioned doctors about two aggressive cases of malignant melanoma that occurred shortly after the drug was administered. Tysabri(r) patients…
Page 1 of 1 pages
